Last updated on December 2019

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)


Brief description of study

The primary objectives of the study are:

  • To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in 50% of tumor cells
  • To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in 50% of tumor cells

The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies

Detailed Study Description

There is option to join genomics sub-study.

Clinical Study Identifier: NCT03088540

Find a site near you

Start Over

Clinical Study Site

Wollongong, Australia
  Connect »

Clinical Study Site

Porto Alegre, Brazil
  Connect »

Clinical Study Site

Mogi Das Cruzes, Brazil
  Connect »

Clinical Study Site

Rio De Janeiro, Brazil
  Connect »

Clinical Study Site

Santa Cecília, Brazil
  Connect »

Clinical Study Site

São José Do Rio Preto, Brazil
  Connect »

Clincial Study Site

Viña Del Mar, Chile
  Connect »

Clinical Study Site

Barranquilla, Colombia
  Connect »

Clinical Study Site

Floridablanca, Colombia
  Connect »

Clinical Study Site

Santa Cecília, Brazil
  Connect »

Clinical Study Site

São José Do Rio Preto, Brazil
  Connect »

Clincial Study Site

Viña Del Mar, Chile
  Connect »

Clinical Study Site

Santa Cecília, Brazil
  Connect »

Clinical Study Site

São José Do Rio Preto, Brazil
  Connect »

Clincial Study Site

Viña Del Mar, Chile
  Connect »

Clinical Study Site

Nový Ji?ín, Czechia
  Connect »

Clinical Study Site 1

Thessaloníki, Greece
  Connect »

Clinical Study Site 2

Thessaloníki, Greece
  Connect »

Clinical Study Site 3

Thessaloníki, Greece
  Connect »

Clinical Study Site

Farkasgyep?, Hungary
  Connect »

Clinical Study Site

Zalaegerszeg, Hungary
  Connect »

Clinical Study Site

Mazraat Ech Choûf, Lebanon
  Connect »

Clinical Study Site

Kampung Baharu Nilai, Malaysia
  Connect »

Clinical Study Site #1

Kuala Lumpur, Malaysia
  Connect »

Clinical Study Site #2

Kuala Lumpur, Malaysia
  Connect »

Clinical Study Site

Pulau Pinang, Malaysia
  Connect »

Clinical Study Site

Tanjong Bungah, Malaysia
  Connect »

Clinical Study Site

León de los Aldama, Mexico
  Connect »

Clinical Study Site

San Luis Potosí, Mexico
  Connect »

Clinical Study Site

Bacolod City, Philippines
  Connect »

Clinical Study Site

Batangas, Philippines
  Connect »

Clinical Study Site

Davao City, Philippines
  Connect »

Clinical Study Site #1

Quezon City, Philippines
  Connect »

Clinical Study Site #2

Quezon City, Philippines
  Connect »

Clinical Study Site

D?browa Górnicza, Poland
  Connect »

Clinical Study Site

Wodzis?aw ?l?ski, Poland
  Connect »

Clinical Study Site

Ufa, Russian Federation
  Connect »

Clinical Study Site

Pushkin, Russian Federation
  Connect »

Clinical Study Site

Arkhangel'sk, Russian Federation
  Connect »

Clinical Study Site

Belgorod, Russian Federation
  Connect »

Clinical Study Site

Chelyabinsk, Russian Federation
  Connect »

Clinical Study Site

Kaluga, Russian Federation
  Connect »

Clinical Study Site

Kazan, Russian Federation
  Connect »

Clinical Study Site

Kemerovo, Russian Federation
  Connect »

Clinical Study Site

Kislino, Russian Federation
  Connect »

Clinical Study Site

Kursk, Russian Federation
  Connect »

Clinical Study Site 1

Moscow, Russian Federation
  Connect »

Clinical Study Site 2

Moscow, Russian Federation
  Connect »

Clinical Study Site 3

Moscow, Russian Federation
  Connect »

Clinical Study Site

Omsk, Russian Federation
  Connect »

Clinical Study Site

Pyatigorsk, Russian Federation
  Connect »

Clinical Study Site 1

Saint Petersburg, Russian Federation
  Connect »

Clinical Study Site 2

Saint Petersburg, Russian Federation
  Connect »

Clinical Study Site 3

Saint Petersburg, Russian Federation
  Connect »

Clinical Study Site 4

Saint Petersburg, Russian Federation
  Connect »

Clinical Study Site

Samara, Russian Federation
  Connect »

Clinical Study Site

Saransk, Russian Federation
  Connect »

Clinical Study Site

Sochi, Russian Federation
  Connect »

Clinical Study Site 1

Tomsk, Russian Federation
  Connect »

Clinical Study Site 2

Tomsk, Russian Federation
  Connect »

Clinical Study Site

Yekaterinburg, Russian Federation
  Connect »

Clinical Study Site

Hualien City, Taiwan
  Connect »

Clinical Study Site 1

New Taipei City, Taiwan
  Connect »

Clinical Study Site

Chiang Rai, Thailand
  Connect »

Clinical Study Site

Phitsanulok, Thailand
  Connect »

Clinical Study Site

Ratchathewi, Thailand
  Connect »

Clinical Study Site

Udon Thani, Thailand
  Connect »

Clinical Study Site

Dnepropetrovsk, Ukraine
  Connect »

Clinical Study Site

Ivano-Frankivs'k, Ukraine
  Connect »

Clinical Study Site

Santa Cecília, Brazil
  Connect »

Clinical Study Site

São José Do Rio Preto, Brazil
  Connect »

Clincial Study Site

Viña Del Mar, Chile
  Connect »

Clinical Study Site

Nový Ji?ín, Czechia
  Connect »

Clinical Study Site 1

Thessaloníki, Greece
  Connect »

Clinical Study Site 2

Thessaloníki, Greece
  Connect »

Clinical Study Site 3

Thessaloníki, Greece
  Connect »

Clinical Study Site

Farkasgyep?, Hungary
  Connect »

Clinical Study Site

Mazraat Ech Choûf, Lebanon
  Connect »

Clinical Study Site

León de los Aldama, Mexico
  Connect »

Clinical Study Site

San Luis Potosí, Mexico
  Connect »

Clinical Study Site

D?browa Górnicza, Poland
  Connect »

Clinical Study Site

Wodzis?aw ?l?ski, Poland
  Connect »